Skip to main content

Table 1 Correlation between expression of ERCC1 and clinicopathological factors of HNSCC

From: High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area

   ERCC1 P Multivariates analysis P
  No. of patients Low expression High expression   OR (95% CI)  
Age       
   50 22 (38.6%) 11 (50.0%) 11 (50.0%) 0.598 1  
   > 50 35 (61.4%) 20 (57.1%) 15 (42.9%)   0.47 (0.11, 2.11) 0315
Gender       
   Male 55 (96.5%) 30 (54.5%) 25 (45.5%) 1.000 1  
   Female 2 (3.5%) 1 (50%) 1 (50%)   48.36 (0.54, 4313.32) 0.090
Tumor Site       
   oral cavity 24 (42.1%) 11 (45.8%) 13 (54.2%) 0.057 1  
   oropharynx 21 (36.8%) 10 (47.6%) 11 (52.4%)   1.58 (0.35, 7.07) 0.549
   hypopharynx/Larynx 12 (21.1%) 10 (83.3%) 2 (16.7%)   0.096 (0.007, 1.33) 0.081
Stage       
   IVa 10 (17.5%) 7 (70.0%) 3 (30.0%) 0.319 1  
   IVb 47(82.5%) 24 (51.1%) 23 (48.9%)   3.33 (0.39, 27.89) 0.276
T stage       
   1/2 6 (10.5%) 6 (100%) 0 (0%) 0.027* 1  
   3/4 51 (89.5%) 25 (49.0%) 26 (51.0%)   Indeterminate 0.999
N stage       
   negative 12 (21.1%) 5 (41.7%) 7 (58.3%) 0.503 1  
   positive 45 (78.9%) 26 (57.8%) 19 (42.2%)   0.75 (0.15, 3.64) 0.727
Alcohol drinking       
   Never 11 (17.2%) 4 (36.4%) 7 (63.6%) 0.318 1  
   Yes 46 (82.8%) 27 (58.7%) 19 (41.3%)   2.49 (0.31, 19.88) 0.388
Smoking       
   Never 9 (15.8%) 3 (33.3%) 6 (66.7%) 0.275 1  
   Yes 48 (84.2%) 28 (58.3%) 20 (41.7%)   1.77 (010, 30.72) 0.695
Betel nuts       
   Never 20 (35.1%) 8 (40.0%) 12 (60.0%) 0.109 1  
   Yes 37 (64.9%) 23 (62.2%) 14 (37.8%)   12.78 (1.28-127.62) 0.030*